Article Text

Download PDFPDF

Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?
Free
  1. A R L Medford,
  2. A B Millar
  1. Lung Research Group, Department of Clinical Medicine at North Bristol, University of Bristol, Southmead Hospital, Westbury-on-Trym, Bristol, UK
  1. Correspondence to:
    Dr A B Millar
    Lung Research Group, Department of Clinical Science at North Bristol, University of Bristol Lifeline Centre, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK; Ann.Millar{at}bristol.ac.uk

Abstract

Acute respiratory distress syndrome (ARDS), the most severe form of acute lung injury (ALI), remains a devastating condition with a high mortality. It is characterised by alveolar injury and increased pulmonary vascular permeability. Vascular endothelial cell growth factor (VEGF) was identified by its properties to increase permeability and act as a cellular growth factor, hence its potential for a key role in the pathogenesis of ALI/ARDS. This review describes the basic biology of VEGF and its receptors as an essential prerequisite to discussing the available and sometimes paradoxical published data, before considering a paradigm for the role of VEGF in the human lung.

  • AE, alveolar epithelial
  • ALI, acute lung injury
  • AP, activator protein
  • ARDS, acute respiratory distress syndrome
  • FLT, fms-like tyrosine kinase
  • HUVEC, human umbilical venous endothelial cell
  • LPS, lipopolysaccharide
  • NRP, neuropilin
  • VEGF, vascular endothelial growth factor
  • VEGF-R1, VEGF-R2, vascular endothelial growth factor receptor 1 and 2
  • vascular endothelial growth factor
  • acute respiratory distress syndrome

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Supported by The Wellcome Trust (074702/Z/04/Z).

  • Competing interests: none.